Jitka Soukupova
Overview
Explore the profile of Jitka Soukupova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soukupova J, Malfettone A, Bertran E, Hernandez-Alvarez M, Penuelas-Haro I, Dituri F, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34073989
(1) Background: The transforming growth factor (TGF)-β plays a dual role in liver carcinogenesis. At early stages, it inhibits cell growth and induces apoptosis. However, TGF-β expression is high in...
2.
Soukupova J, Bordoni C, Turnham D, Yang W, Seaton G, Gruca A, et al.
Mol Cancer Ther
. 2021 Mar;
20(5):775-786.
PMID: 33649105
The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options...
3.
Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S, et al.
Cell Death Dis
. 2018 Mar;
9(3):373.
PMID: 29515105
Cancer stem cells (CSCs) niche in the tumor microenvironment is responsible for cancer recurrence and therapy failure. To better understand its molecular and biological involvement in hepatocellular carcinoma (HCC) progression,...
4.
Soukupova J, Bertran E, Penuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H, et al.
Oncotarget
. 2018 Jan;
8(66):110367-110379.
PMID: 29299154
Conclusion: Resminostat shifts mesenchymal cells towards a more epithelial phenotype, lower invasive and stemness properties, which may contribute to the sensitization to sorafenib-induced apoptosis.
5.
Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism
Soukupova J, Malfettone A, Hyrossova P, Hernandez-Alvarez M, Penuelas-Haro I, Bertran E, et al.
Sci Rep
. 2017 Oct;
7(1):12486.
PMID: 28970582
Transforming Growth Factor beta (TGF-β) induces tumor cell migration and invasion. However, its role in inducing metabolic reprogramming is poorly understood. Here we analyzed the metabolic profile of hepatocellular carcinoma...
6.
Hanafy N, Quarta A, Di Corato R, Dini L, Nobile C, Tasco V, et al.
J Mater Sci Mater Med
. 2017 Jul;
28(8):120.
PMID: 28685231
TGFβ1 pathway antagonists have been considered promising therapies to attenuate TGFβ downstream signals in cancer cells. Inhibiting peptides, as P-17 in this study, are bound to either TGFβ1 or its...
7.
Malfettone A, Soukupova J, Bertran E, Crosas-Molist E, Lastra R, Fernando J, et al.
Cancer Lett
. 2017 Feb;
392:39-50.
PMID: 28161507
As part of its potential pro-tumorigenic actions, Transforming Growth Factor-(TGF)-β induces epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) cells. Whether EMT induces changes in tumor cell plasticity has not been...
8.
Fabregat I, Malfettone A, Soukupova J
J Clin Med
. 2016 Mar;
5(3).
PMID: 26985909
The epithelial-mesenchymal transition (EMT) is an example of cellular plasticity, where an epithelial cell acquires a mesenchymal-like phenotype that increases its migratory and invasive properties. Stemness is the ability of...
9.
Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller W, et al.
Cancer Res
. 2012 Nov;
73(2):745-55.
PMID: 23149915
Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tumors. Studies in cell lines suggest that its oncogenic effects are mediated through the induction of proliferation and inhibition of...
10.
Brahemi G, Kona F, Fiasella A, Buac D, Soukupova J, Brancale A, et al.
J Med Chem
. 2010 Mar;
53(7):2757-65.
PMID: 20222671
The zinc-ejecting aldehyde dehydrogenase (ALDH) inhibitory drug disulfiram (DSF) was found to be a breast cancer-associated protein 2 (BCA2) inhibitor with potent antitumor activity. We herein describe our work in...